USPTO serial 79402228
NANOREADY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 29, 2025
- Examiner
- BLAKESLEE, RICHARD A
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NANOREADY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
KR
KR
KR
KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Richard Y. Kim
Richard Y. Kim Snell & Wilmer L.L.P.One East Washington Street, Suite 2700Phoenix, AZ 85004-2556United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for health care, in particular for the prevention and treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases and for use in genetic therapy for the prevention and treatment of genetic disorders; medicine cases, portable, filled, in the nature of first-aid kits; vaccines; food supplements; vitamin and mineral dietary supplements; veterinary substances and preparations for the prevention and treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases and for use in genetic therapy for the prevention and treatment of genetic disorders; medicinal preparations for the mouth in the form of drops, capsules, tablets, or compressed tablets for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases, infectious diseases, and genetic disorders; ointments for pharmaceutical purposes for the treatment of pain, inflammation and skin disorders; cachets for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases, infectious diseases, and genetic disorders; pharmaceutical preparations being adrenal, parathyroid, pituitary, pancreas, and salivary gland hormone preparations for human use; ferments for pharmaceutical purposes; pre-moistened medicated tissues; pharmaceutical preparations, namely, elixirs for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases, infectious diseases, and genetic disorders; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases, infectious diseases, and genetic disorders; pharmaceutical drugs, namely, pharmaceutical preparations for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases, infectious diseases, and genetic disorders; human vaccine preparations; medicines for human purposes, namely, pharmaceutical preparations for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases, infectious diseases, and genetic disorders; pharmaceutical preparations for the treatment of cancer; nutraceutical preparations for therapeutic or medical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases, infectious diseases, and genetic disorders; antibiotics; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules sold empty and tablets that provide controlled release of the active ingredients that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of coatings for tablets that facilitate the delivery of nutritional supplements | ACTIVE | — |
| 010 | Surgical gloves; surgical apparatus and instruments for veterinary use; veterinary apparatus, namely, electrocardiographs, X-ray apparatus, ultrasound apparatus and medical imaging apparatus for veterinary purposes; surgical instruments for use in general surgery; surgical sutures; surgical apparatus and instruments for medical, dental or veterinary use; medical instruments for use in general surgery; medical apparatus, namely medical radiation apparatus, medical X-ray apparatus, and medical imaging apparatus; medical instruments, namely medical hearing instruments; sanitary masks for medical use; cold-hot massage apparatus for medical use; suture materials for medical use; surgical apparatus and instruments for medical use; thread for medical use; protective face masks for medical use; gloves for medical purposes; medical apparatus, namely, medical apparatus for detecting cancer, medical imaging apparatus, ultrasonic medical diagnostic apparatus; apparatus for drug administration, namely, infusion and injection devices for administering drugs; syringes for injection of medical substances; orthopedic articles, namely, orthopedic belts, orthopedic soles, orthopedic footwear, orthopedic bandages, orthopedic bandages for joints and orthopaedic hosiery, and orthopedic apparatus and instruments for diagnostic and therapeutic use; dental instruments, namely root canal therapy instruments used to shave the inside of a root canal, dental root files used in root canal therapy procedures, reusable and recyclable prophy angles, prophy angles, disposable prophy angles, oral irrigators, hemostats that clamp blood vessels to diminish or halt blood flow, crown and bridge removers | ACTIVE | — |
| 040 | Custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials; preservation of pharmaceuticals; custom manufacture of pharmaceuticals; destruction of medical waste; custom manufacture of medical devices for others; custom assembling of electronic components for medical devices; recycling of medical waste; processing of pharmaceuticals being custom manufacture of pharmaceuticals; manufacture of custom dental bridges for others; custom manufacture of dental prosthesis and dentures; processing and treatment of chemical reagents | ACTIVE | — |
| 042 | Research and development of vaccines and medicines; biological information check, namely, genetic testing for medical research purposes; pharmaceutical research services; inspection of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; services for assessing the efficiency of pharmaceuticals, namely, product quality testing services; technological and scientific remote monitoring services relating to medical diagnostic devices, namely, remote monitoring of medical diagnostic systems for quality control purposes; medical research laboratories; providing computer software technical support services, namely, troubleshooting of computer software problems in the field of medical diagnostics; providing technological support services regarding medical diagnostic instruments, namely, troubleshooting of computer software problems; scientific research relating to medicines; analysis and evaluation of medical product development; testing of pharmaceuticals; laboratory research services relating to pharmaceuticals; providing information on the testing, inspection and scientific research of medical products; consultancy in the field of testing, inspection, and scientific research of medical products; blood testing for scientific medical research purposes; engineering services in the field of medical technology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Samyang Holdings Corporation
- Other trademarks owned by SAMYANG BIOPHARM CORPORATION
- Other trademarks owned by Samyang Holdings Corporation
- Other trademarks owned by Samyang Holdings Corporation
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named NANOREADY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 4, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 19, 2026 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Jan 29, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 14, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 14, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Dec 11, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 23, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 23, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 30, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 29, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 29, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 11, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 11, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 5, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 18, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 13, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 13, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 13, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 1, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 10, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 10, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 19, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 18, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 17, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 21, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 21, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 15, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |